HC Wainwright Issues Positive Forecast for Vericel (NASDAQ:VCEL) Stock Price

Vericel (NASDAQ:VCEL) had its target price lifted by HC Wainwright from $72.00 to $75.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Vericel’s Q4 2026 earnings at $0.62 EPS and Q4 2027 earnings at $0.53 EPS.

Other equities analysts have also issued reports about the company. Truist Financial dropped their price target on Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. TD Cowen raised their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research report on Thursday, July 30th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.80.

Vericel Price Performance

Shares of VCEL traded up $2.84 during trading hours on Friday, hitting $54.62. 1,612,332 shares of the stock were exchanged, compared to its average volume of 564,100. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $55.60. The business has a 50-day moving average of $41.01 and a 200-day moving average of $38.90. The firm has a market capitalization of $2.80 billion, a P/E ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 earnings per share. As a group, analysts forecast that Vericel will post 0.54 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jonathan Siegal sold 1,500 shares of Vericel stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.90, for a total value of $79,350.00. Following the completion of the sale, the insider owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. This trade represents a 54.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 3,000 shares of Vericel stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total transaction of $156,690.00. Following the completion of the sale, the director directly owned 32,995 shares of the company’s stock, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 22,000 shares of company stock worth $1,128,340 over the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. MCF Advisors LLC increased its position in shares of Vericel by 293.0% during the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 583 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Vericel in the 2nd quarter valued at about $36,000. Allworth Financial LP bought a new position in Vericel in the 2nd quarter valued at about $60,000. Meeder Asset Management Inc. bought a new position in Vericel in the 1st quarter valued at about $61,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Vericel during the 2nd quarter valued at about $72,000.

Key Stories Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.